-
How much weight loss occurs with Exenatide
in real clinical use.
-
How much HbA1c reduction occurs with
Exenatide in real clinical use.
-
Who are the patients who respond especially
well to Exenatide in real clinical use – does it relate to duration of
diabetes, or body mass index, or particular other medications being used
etc. Is it possible to predict the patients who are more likely to
respond to Exenatide.
-
Similarly, who are the patients who don’t respond
to Exenatide?
-
Currently Exenatide usage with insulin is
off license but many diabetologists have tried it with insulin. The
nationwide audit affords an opportunity to pool experience of usage of
Exenatide with insulin across the nation, find out how useful this
approach is, the extent to which insulin dose is reduced or insulin is
even stopped. The data may help bring forward the licensing of usage of
Exenatide with insulin.
-
Is pancreatitis a real issue with Exenatide?
-
What are the side effects? Are there any
important ones that have not yet been identified?
-
If there are problems with Exenatide which may come out
in due course as possibly may occur with Rosiglitazone, can we get some
forewarning of any possible problems now through pooling
the national experience.
-
To what extent does Exenatide allow avoidance of
insulin and continuation in their jobs for professional
drivers?
-
What is the size of the problem of hypoglycaemia
with Exenatide and insulin, or Exenatide and sulphonylureas. Is there a
problem of worsening hyperglycaemia if insulin is stopped and Exenatide
started? Are there guidelines that can be deduced from the nationwide
expereience with regard to how to add Exenatide to insulin and how to
add Exenatide to sulphonylureas without inducing hypoglycaemia or
hyperglycaemia.
-
What percentage of patients cannot tolerate
Exenatide in real clinical use?
-
Is the clinical efficacy of Exenatide sustained?
Does the weight loss continue with time or does it plateau off?
-
Are there benefits, or otherwise, in combining of
thiazolidediones and exenatide
-
Could we, from the data, calculate the potential benefit
in terms of predicting cardiovascular event reduction on
the as yet unvalidated assumption that the reduction in risk factors is
translated into prevention of cardiovascular events?
